DSpace DSpace

University of Minnesota Digital Conservancy >
University of Minnesota - Twin Cities >
INNOVATIONS in pharmacy >
Volume 03, Number 1, 2012 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/11299/122763

Title: Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access Hospitals
Authors: Wallack, Madeline Carpinelli
Sorensen, Todd
Keywords: 340B Drug Discount Program
Critical Access Hospitals
Orphan Drugs
Issue Date: 2012
Publisher: University of Minnesota, College of Pharmacy
Citation: Wallack MC, Sorensen T. Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access Hospitals. Innov. Pharm. 2012; 1(70):1-7.
Abstract: Purpose: The 340B Drug Pricing Program is a federal program designed to reduce the amount that safety net providers spend on outpatient drugs. The Patient Protection and Affordable Health Care Act of 2010 extended eligibility for 340B to critical access hospitals (CAHs) for all drugs except those designated as “orphan.” Because this policy is unprecedented, this study quantifies the gross financial impact that this exemption has on a group of CAHs. Methods: Drug spending for 2010 from 18 CAHs in Minnesota and Wisconsin are reviewed to identify the prevalence of orphan drug purchases and to calculate the price differentials between the 340B price and the hospitals’ current cost. Results: The 18 CAHs’ purchases of orphan drugs comprise an average of 44% of the total annual drug budgets, but only 5% of units purchased, thus representing a very high proportion of their expenditures. In the aggregate, the 18 hospitals would have saved $3.1 million ($171,000 average per hospital) had purchases of drugs with orphan designations been made at the 340B price. Because CAH claims for Medicare are reimbursed on a cost-basis, the Federal government is losing an opportunity for savings. Conclusion: The high prevalence of orphan drug use and considerable potential for cost reduction through the 340B program demonstrate the loss of benefit to the hospitals, Federal government and the states.
URI: http://purl.umn.edu/122763
ISSN: 2155-0417
Appears in Collections: Volume 03, Number 1, 2012

Files in This Item:

File Description SizeFormat
(12-089) Excluding Orphan Drugs_article 70.pdf487.54 kBPDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.